IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma by Conroy, Siobhan et al.
  
 University of Groningen
IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Conroy, S., Kruyt, F. A. E., Wagemakers, M., Bhat, K. P. L., & den Dunnen, W. F. A. (2018). IL-8
associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. Oncotarget, 9(21), 15721-
15731. https://doi.org/10.18632/oncotarget.24595
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget15721www.oncotarget.com
IL-8 associates with a pro-angiogenic and mesenchymal subtype in 
glioblastoma
Siobhan Conroy1,2, Frank A.E. Kruyt3, Michiel Wagemakers4, Krishna P.L. Bhat2,* 
and Wilfred F.A. den Dunnen1,*
1Department of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands
2Department of Translational Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
3Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
*These authors share senior authorship
Correspondence to: Wilfred F.A. den Dunnen, email: w.f.a.den.dunnen@umcg.nl
Keywords: glioblastoma; subclasses; angiogenesis; IL-8
Received: September 07, 2017 Accepted: February 10, 2018 Epub: February 28, 2018 Published: March 20, 2018 
Copyright: Conroy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by a high 
rate of vascularization. However, therapeutic targeting of the vasculature through 
anti-vascular endothelial growth factor (VEGF) treatment has been disappointing, 
for which Angiopoietin-2 (Ang-2) upregulation has partly been held accountable. 
In this study we therefore explored the interplay of Ang-2 and VEGFA and their 
effect on angiogenesis in GBM, especially in the context of molecular subclasses. In a 
large patient cohort we identified that especially combined high expression of Ang-2 
and VEGFA predicted poor overall survival of GBM patients. The high expression of 
both factors was also associated with increased IL-8 expression in GBM tissues, but  
in vitro stimulation with Ang-2 and/or VEGFA did not indicate tumor or endothelial 
cell-specific IL-8 responses. Glioblastoma stem cells (GSCs) of the mesenchymal (MES) 
subtype showed dramatically higher expression of IL8 when compared to proneural 
(PN) GSCs. Secreted IL-8 derived from MES GSCs  induced endothelial proliferation and 
tube formation, and the MES GBMs had increased counts of proliferating endothelial 
cells. Our results highlight a critical pro-angiogenic role of IL-8 in MES GBMs.
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INTRODUCTION
Glioblastoma (GBM) is the most common and 
aggressive primary brain tumor in adults [1, 2]. Current 
standard of care comprises maximal safe surgical resection 
with concurrent chemo-radiation followed by maintenance 
chemotherapy [3, 4]. Despite application of optimal 
treatment, the prognosis of patients diagnosed with GBM 
has remained rather disappointing with a median survival 
of only 15 months [4]. Development of more effective 
therapies are therefore urgently needed. Given the highly 
vascularized nature of GBMs and the correlation between 
tumor angiogenesis and disease severity [5–7], the 
potential of therapy targeting the vascular compartment 
has been intensively studied.
Vascular endothelial growth factor A (VEGFA) is a 
central player in angiogenesis and can be induced by a variety 
of angiogenic signaling pathways as well as hypoxia [8–10]. 
Therapeutic targeting of VEGFA and its corresponding 
receptors has therefore been assessed broadly. For example, 
anti-VEGFA therapy using Bevacizumab was initially 
proven to be successful in recurrent GBM [11, 12], but the 
results of Phase III Bevacizumab trials in newly diagnosed 
GBM have provided less encouraging results [13, 14]. 
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Although Bevacizumab treatment in newly diagnosed GBMs 
resulted in an increase in progression-free survival (PFS), 
an effect on overall survival (OS) was never observed. This 
response pattern possibly reflects an initial effect of the 
therapy, which is later compromised by the development of 
resistance mechanisms. A potential resistance mechanism 
could be the exploitation of alternative angiogenic signaling 
pathways, and due to the strong dependency of VEGF 
signaling on Angiopoietin/Tie-2 (Ang/Tie-2) signaling, this 
pathway is of particular interest for treatment resistance. 
Ang/Tie-2 signaling involves the competitive 
binding of the ligands angiopoietin-1 (Ang-1) and 
angiopoietin-2 (Ang-2) to their receptor Tie-2 [15, 16]. 
Ang-1 binding to Tie-2 results in vessel stabilization, 
while Ang-2 binding results either in vessel destabilization 
in the absence of VEGFA or in vessel proliferation when 
VEGFA is present. The Ang-1/Ang-2 ratio was found to 
correlate with OS in GBM patients and high levels of 
Ang-2 correlated with resistance to anti-VEGFA therapy 
[17, 18]. Ectopic expression of Ang-2 in GBM cells 
was found to mediate the diminished effects of anti-
VEGF therapy by increasing vascular permeability in 
mouse models [19]. Alternatively, elevated Ang-2 levels 
following treatment also increases attraction of bone 
marrow derived cells that assist perivascularly in the 
protection of vulnerable vasculature [20]. Therapeutic 
targeting of Ang-2 has shown broad anti-tumor activity 
in a number of preclinical solid tumor models, and the 
addition of anti-Ang-2 treatment to cytotoxic drugs or 
anti-VEGF treatment has resulted in superior effects over 
single-agent therapy alone [21, 22]. Two recent studies 
used this combination approach in preclinical GBM 
models and both studies indicated superb effects of the 
addition of Ang2-inhibition to anti-VEGFA monotherapy 
[23, 24]. 
In the current study we evaluated the association 
of Ang-2 and VEGFA expression in GBMs with patient 
survival and vascularization patterns. The signaling levels 
through alternate angiogenic signaling pathways were 
quantified and led to the identification of IL-8 upregulation 
in pro-angiogenic and MES GBMs. The functional role 
of this signaling route was explored through in vitro 
angiogenesis assays and immunohistochemistry on patient 
GBM tissue.
RESULTS
High expression of ANGPT2 and VEGFA is 
associated with a worse prognosis and IL-8 
upregulation
The expression levels of the pro-angiogenic factors 
Ang-2 and VEGFA were determined in 525 patients with 
GBM obtained from the TCGA cohort (n = 525) and was 
examined for possible correlation with OS. Patients were 
divided into high and low expressing tumors based on the 
median expression level. The Kaplan-Meier analysis of 
these groups revealed that high expression of ANGPT2 
(P < 0.01) and VEGFA (P < 0.05) was independently 
associated with a worse prognosis (Figure 1A, 1B). Then 
a combination variable was constructed to separate tumors 
with high expression of both ANGPT2 and VEGFA 
(ANGPT2*VEGFAhigh) from the other tumors. Kaplan-
Meier analysis of this stratification of patients revealed 
that the combined high expression of these pro-angiogenic 
factors was also associated with worse survival (P < 0.001, 
Figure 1C). 
A Cox regression analysis was performed to 
compare the prognostic value of ANGPT2, VEGFA 
and the combined high expression of both factors, 
which indicated that only the combined high expression 
maintained significant prognostic value (P = 0.040, Table 2). 
These results were replicated in the REMBRANT cohort (n = 
151), and subsequently the prognostic value of the angiogenic 
factors was also assessed in a Cox regression that included the 
known prognostic factors age at diagnosis and KPS. In this 
model only age at diagnosis and KPS maintained prognostic 
significance (Supplementary Table 1). Of the angiogenic 
factors ANGPT2*VEGFA had the highest HR. 
To further assess the role of Ang-2 and VEGFA 
in GBM angiogenesis a set of 28 tumors was assembled 
(Groningen cohort). Similar to the survival analyses, this 
cohort was also subdivided in groups based on differential 
expression of ANGPT2, VEGFA or a combination of both. 
The microvascular density (MVD) was analyzed on tissue 
sections for the number of vessels per mm2, average vessel 
area (size) and vessel perimeter, but all MVD-parameters 
did not differ significantly between tumors in association 
with ANGPT2 and/or VEGFA expression (Figure 1D–1F). 
We then continued with profiling of the angiogenic 
signaling of the Groningen cohort. The comparison of 
tumors with above median expression of ANGPT2 and 
VEGFA with the other GBMs showed several significant 
differences between these groups, with IL8 and MMP9 
as the strongest upregulated transcripts in the angiogenic 
subgroup (ANGPT2*VEGFAhigh, Figure 1G). In addition 
DLL4, FLT1, MMP2, NOTCH4 and PGF were also found 
to be upregulated in these tumors. MMP proteins serve 
an important role in angiogenesis as they degrade the 
extracellular matrix, of which MMP2 and MMP9 were 
both significantly upregulated in the ANGPT2*VEGFAhigh 
group. As the natural inhibitors of both MMPs were also 
slightly elevated, the relative increase of both proteinases 
(MMP2/TIMP1 and MMP9/TIMP2) was not significant. 
Since IL-8 is well-known for its pro-angiogenic effects we 
decided to focus on this target.
The expression of ANGPT2 and VEGFA is 
associated with IL8 expression
The results from the Groningen cohort indicating 
that IL8 expression is higher in tumors that also have 
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higher than median expression of ANGPT2 and VEGFA 
was then further explored in both the Groningen and 
TCGA cohort. In the smaller Groningen cohort, the 
GBMs were dichotomized as those above or below median 
ANGPT2 and/or VEGFA expression as described above. 
In all these groups higher expression levels of ANGPT2 
and/or VEGFA were associated with increased IL8 levels 
(Figure 2A–2C). Similarly, results obtained from the 
TCGA cohort confirmed the patterns observed in the 
Groningen cohort (Supplementary Figure 1).
Additionally, correlations between the expression 
levels of these three factors were assessed in the larger 
TCGA cohort. Significant positive correlations were 
identified between ANGPT2 and IL8 (r = 0.4532, P 
< 0.001, Figure 2D), VEGFA and IL8 (r = 0.5909, P < 
0.001, Figure 2E) and between ANGPT2 and VEGFA 
(r = 0.6312. P < 0.001, Figure 2F). The analyses in the 
Groningen cohort only reproduced the association between 
ANGPT2 and IL8 expression (r = 0.7093, P < 0.01, Online 
Resource 4), but did not identify any other correlations.
Effects of Ang-2 and VEGFA stimulation on 
tumor and endothelial cells
To explore whether the expression level of IL-8 can 
be modulated by Ang-2 or VEGFA we continued with 
the stimulation of HMEC-1s using recombinant Ang-2 
and VEGFA proteins. The concentration used for Ang-2 
(400 ng/ml) and VEGFA (100 ng/ml) were chosen 
based on results in tube formation assays in which 
they produced inhibitory and stimulatory effects, 
respectively (data not shown). The single or dual 
stimulation did not significantly alter proliferation 
or apoptosis in HMEC-1 cells (Figure 3A, 3B), but 
Figure 1: Combined high expression of Ang-2 and VEGFA associates with survival and increased IL-8 expression. 
The expression level of ANGPT2 (A), VEGFA (B) and the combined high expression of ANGPT2 and VEGFA (C) associated with poorer 
survival of GBM patients (TCGA cohort). The differential expression of these factors (above or below median) did not associate with 
microvascular density (D), vessel size (E) or vessel perimeter (F) (Groningen cohort). Individual values per patient are displayed and 
horizontal lines represent median scores. (G) Profiling of several angiogenic mRNAs identified IL8 and MMP9 as the targets upregulated 
most in the tumors with combined high expression of ANGPT2 and VEGFA; *P < 0.05, **P < 0.01.
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especially VEGFA stimulation induced IL8 transcription 
1, 4 and 24 hours after stimulation (Figure 3C). 
This induction did not translate into significantly different 
secretion levels of IL-8 protein (Figure 3D). 
The dual stimulation of U87 cells inhibited 72-hour 
proliferation by 11 percent (P < 0.05, Figure 3E), but did 
not induce apoptosis (Figure 3F). The induction of IL8 
transcription detected in HMEC-1 was less pronounced 
in U87 cells treated with Ang-2 and VEGFA (Figure 3G). 
IL-8 secretion by U87 cells following stimulation was 
relatively unaffected (Figure 3H), similar to the effects 
observed in HMEC-1 cells.
MES subtype associates with increased 
IL8 expression and IL-8 mediates in vitro 
angiogenesis
We then shifted our focus to GBM stem-like 
cells (GSCs) that have been shown to better reflect the 
phenotype of the human disease [25, 26]. GBMs of the 
MES subtype have been reported to express higher levels 
of angiogenic markers than their PN counterparts [27]. 
Analyses of gene expression in MES GBMs showed 
higher mRNA levels of ANGPT2, VEGFA and IL8 (TCGA 
cohort, Figure 4A–4C). The TCGA analysis was then 
followed up with in vitro experimentation with a panel of 
GSCs representative of the PN and MES phenotype that 
have been described previously [28]. The MES GSCs 
exhibited a dramatically higher expression of IL8 mRNA 
in comparison to PN GSCs (P < 0.001, Figure 4D). Unlike 
in HMEC-1s and U87 cells, the mRNA expression in MES 
GSCs correlated with a concordantly higher IL-8 protein 
secretion (P < 0.001, Figure 4E). 
To test whether IL-8 would be capable of inducing a 
MES transition in PN GSCs we treated PN GSCs (GSC11 
and 23) with recombinant human IL-8 and tested the 
induction of master MES transcriptional regulators at 
different time points. There were only minor differences 
between control and stimulated cells regarding STAT3, 
CEBPB and TAZ expression (Supplementary Figure 2), 
leading us to conclude that IL-8 did not directly control the 
MES transition of the PN GSCs. We therefore continued 
with the exploration of the paracrine effect of PN and 
MES GSCs on endothelium.
The functional impact of IL-8 secretion on 
angiogenesis was then further addressed through the 
use of conditioned medium (CM) from PN and MES 
GSCs. The treatment of endothelial cells with GSC CM 
in general did not substantially affect endothelial cell 
proliferation, but interestingly the addition of an IL-8 
neutralizing antibody only resulted in a partial (non-
significant) inhibition when added to CM from MES 
GSC28 (Figure 4F). Similarly, in tube formation assays 
CM from both GSC subtypes generally enhanced the rate 
of tube formation compared to controls (Figure 4G, 4H), 
but the addition of the IL-8 neutralizing antibody only 
prevented the enhancement of tube formation in the case 
of MES CM. These results together illustrate that IL-8 is 
an important mediator of MES-induced angiogenesis in 
GBM.
Figure 2: Ang-2 and VEGFA expression associate with increased IL-8 expression. In the Groningen cohort tumors with higher 
than median ANGPT2 expression (A) and tumors with higher than median expression of ANGPT2 and VEGFA (C) expressed significantly 
higher levels of IL-8 mRNA as well. A similar but non-significant trend was observed for tumors with above median expression of VEGFA 
(B). Box-and-whiskers were generated according to Tukey’s method with the box representing the 25th and 75th percentile, and whiskers 
represent 1.5 × IQR. Values outside these intervals are plotted as individual points. The expression levels of ANGPT2 (D), VEGFA (E) and 
IL-8 (F), explored in the larger TCGA cohort, were all positively correlated; *P < 0.05, ***P < 0.001.
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MES GBMs have more proliferating endothelial 
cells 
To test the hypothesis that MES GBMs have 
higher levels of IL-8 which could serve as signals for 
angiogenesis, the level of dividing endothelial cells was 
quantified on GBM tissue from patients. The average 
number of double-stained cells for CD34 (endothelial 
marker) and Ki-67 (proliferation marker) was confirmed 
to be higher in MES GBMs (P < 0.01, Figure 5A, 5B). 
In summary of these findings we propose a model in 
which MES GSCs secrete IL-8 that affects the survival 
and proliferation of endothelial cells in a paracrine fashion 
(Figure 5C). 
DISCUSSION
In previous studies it has been shown that ANGPT2 
and VEGFA individually are associated with a worse 
prognosis for GBM patients [5, 17, 29]. In this study, 
we showed that the combined higher expression of 
ANGPT2 and VEGFA is even stronger associated with 
a worse prognosis in two independent cohorts, although 
this combination factor did not qualify as an independent 
prognostic variable in a multivariate analysis including 
the known prognostic factors age and KPS. Functionally, 
increased expression of Ang-2 and VEGFA could not 
be linked to increased vascularity, but the examination 
of an angiogenic transcriptional profile identified a 
strong association between high ANGPT2 and VEGFA 
expression and IL8 expression.
IL-8, a chemokine also known as CXCL8, was 
initially discovered for its pro-inflammatory functions, but 
the contributions of IL-8 to other tumorigenic processes 
are now well documented [30, 31]. IL-8 expression is 
associated with glioma grade [32], and within GBMs, 
a 3-fold higher expression of IL-8 was associated with 
diminished patient survival [33]. The suppression of the 
upstream regulator ING4 illustrated the pro-tumoral effects 
of enhanced IL-8-signaling in an in vivo GBM model [34], 
which was tightly related to increased vascularity. Another 
study confirmed that IL-8 in the secretome of GBM cells 
was a major pro-angiogenic factor through endothelial 
CXCR2-signaling [33]. Since we also initially discovered 
the association between a pro-angiogenic phenotype and 
elevated IL-8 expression, we focused this study on the role 
of IL-8 in GBM angiogenesis. 
In addition to the association with the pro-angiogenic 
phenotype, the expression of IL-8 was also found to be 
elevated in MES GBMs. Molecular GBM subtypes that 
Figure 3: Effect of Ang-2 and/or VEGFA stimulation on U87 GBM cells and HMEC-1 endothelial cells. The proliferation 
(A) and rate of CC3-mediated apoptosis (B) in HMEC-1 was unaltered following stimulation with Ang-2 and/or VEGFA after 72 and 24 
hours, respectively. The transcription of IL8 was upregulated mainly following VEGFA stimulation at different time points (C), but the 24-
hour secretion level of IL-8 was unaltered in HMEC-1 cells (D). The proliferation of U87 cells was slightly inhibited after dual stimulation 
with Ang-2 and VEGFA (E), but CC3-mediated apoptosis levels were unaltered (F). VEGFA induced upregulation of IL-8 transcription 
in U87 only at the 1-hour time point (G), but 24-hour secretion levels of IL-8 were indifferent between the conditions (H). Assays were 
repeated three times and mean values ± standard deviations are displayed; *P < 0.05, **P < 0.01, ***P < 0.001 all relative to control.
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associate with survival and response to therapy have been 
described previously, and the MES subtype was initially 
described as the more vascularized and angiogenic subtype 
[27, 35]. We have previously reported that MES GBMs 
do have larger but not necessarily more vessels, and the 
angiogenic signaling profile of the PN, classical (CLAS) 
and MES subtypes were rather similar [48]. In this study 
we looked at the PN and MES subtype and found a clear 
Figure 4: IL-8 is upregulated in MES GSCs and mediates in vitro angiogenesis. Expression levels of ANGPT2, VEGFA, and 
IL8 mRNA are upregulated in MES versus PN GBMs (TCGA cohort, A–C). MES GSCs (GSC 20, 28 and 267) display higher levels of the 
mRNA transcript in comparison to PN GSCs (GSC 8-11, 11 and 23) (D). The secretion level of IL-8 also indicated increased IL-8 secretion 
by MES GSCs in comparison to PN GSCs (E). CM of GSCs only had minor effects on HMEC-1 proliferation, with a trend for inhibition of 
HMEC-1 proliferation when an IL-8 was neutralized in MES GSC28 CM (F). Representative images of tube formation assays are displayed 
(G) that illustrate enhanced tube formation by the addition of MES CM and significant inhibition of tube formation when IL-8 is neutralized 
in GSC28 CM (H). The variation in individual assays is also shown (I, J). Assays were repeated five (proliferation) or six (tube formation) 
times and mean values with standard error of the mean (SEM) are plotted; *P < 0.05, ***P < 0.001.
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upregulation of IL8 expression in and secretion from MES 
GSCs, and we showed that IL-8 is a key mediator of the 
paracrine pro-angiogenic effect of MES GSCs. 
The effects observed with the in vitro tube formation 
however support these conclusions better than the 
proliferation data. Worth noting in this regard was the 
requirement of serum addition for HMEC-1 maintenance 
in proliferation assays but not in tube formation assays, 
which experimentally complicated the detection of 
isolated IL-8 effects orchestrated via GSC CM amidst 
reduced but substantial levels of human and fetal bovine 
serum in the culture medium during proliferation assays. It 
is therefore possible that under better controlled conditions 
the paracrine effect of IL-8 on endothelial proliferation 
could be stronger, and with the higher secretion levels of 
IL-8 from MES GSCs it is imaginable that these effects 
will be more pronounced in GBMs of the MES subclass.
Previous studies in other tumor entities have shed 
light on the effect of IL-8 on the tumor cell compartment, 
but since the responses detected in the GSCs were limited 
we primarily focused on the paracrine effect of IL-8 on 
endothelial cells. In epithelial cancers, IL-8 has been 
reported to induce an epithelial-to-mesenchymal transition 
(EMT) [36], which was also shown in relatively more 
differentiated GBM models through IL-8-mediated F-actin 
polymerization [37]. Besides the notion that IL-8 can 
regulate GSC stemness in the perivascular niche [38], the 
pro-tumorigenic effects of IL-8 in GBM are quite unclear. 
Whether GBM cells express the IL-8 receptors (CXCR1 
and CXCR2) is an ongoing debate and conflicting data 
have been reported [30, 39–41]. Since the treatment of our 
PN GSCs did not induce an upregulation of the important 
MES transcriptional regulators STAT3, C/EBPβ and TAZ 
[42, 43], we hypothesize that IL-8 upregulation is not 
necessarily instructive for the MES subtype of these GSCs, 
but moreover a side-effect of the subclass transcriptional 
pattern that is active in the tumor cells. With binding sites 
present for AP-1 and NF-κB in the promoter region of IL-8, 
maintenance of IL-8 expression in MES GBMs is likely 
sustained. GBMs of the MES subtype generally suffer 
more from hypoxia and in hypoxic glioma cultures, AP-1 
functions as a critical oxygen-sensitive transcriptional 
factor for IL-8 [40, 48], while NF-κB is highly expressed 
in MES GSCs and regulates the MES differentiation [28]. 
Another prominent characteristic of MES GBMs 
is tumor cell invasion of which IL-8 is known to be a 
potent inducer. An IL-8 neutralizing antibody as well as a 
CXCR1 blocking antibody significantly inhibited glioma 
cell invasion in vitro [41]. Since it was also shown that 
IL-8 can directly enhance the protease production in 
endothelial cells [44], we speculate that targeting of the 
IL-8 signaling axis could also affect tumor invasiveness. 
In summary, we showed that the combined high 
expression of Ang-2 and VEGFA is a stronger prognostic 
factor than Ang-2 and VEGFA alone. This pro-angiogenic 
phenotype is strongly associated with increased IL-8 
expression, and we propose that this factor has a key role 
in pro-angiogenic signaling of tumor cells in MES GBMs. 
Given the diverse involvement of IL-8 in gliomagenesis, 
further exploration of its role and potential druggability in 
especially highly angiogenic and MES GBMs could be a 
promising path for future studies.
METHODS
Patient populations
Data were retrieved of two independent GBM 
cohorts from public data repositories made available by the 
Cancer Research Network (TCGA, http://cancergenome.
nih.gov/) and the National Cancer Institute of the United 
States (Repository for Molecular Brain Neoplasia Data 
[REMBRANDT]) [45, 46]. The third cohort concerned the 
Groningen cohort that comprised an additional set of 28 
GBMs on which the vascular assessments were performed. 
The details and clinical characteristics of the cohorts are 
summarized in Table 1, and additional experimental details 
are reported in the Supplementary Materials.
All experiments including the use of human tissue 
were in accord with the Declaration of Helsinki and 
were conducted under the ‘code of conduct for dealing 
responsibly with human tissue in the context of health 
Figure 5: MES GBMs have more proliferating endothelial cells. A photomicrograph of a double stained GBM sample for CD34 
in red and Ki67 in brown is depicted (A). The black arrowheads indicate CD34+Ki67+ cells. Scale bar is 100 µm. Quantification of the double 
stained cells indicated that MES GBM tissue had a significantly higher percentage of PECs in comparison to the PN GBM tissues (B). 
(C) Proposed model of vessel expansion due to increased IL-8 secretion by MES GSCs ; Scale bar = 100 µm; **P < 0.01.
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research’ published by the Federation of Dutch Medical 
Scientific Societies in 2011 [47]. The research was 
performed on the leftover material and all tissues were 
handled coded and anonymously.
Survival analyses
For the survival analyses the TCGA and 
REMBRANDT cohort were stratified into below and 
above median expression groups for Ang-2 and VEGFA 
expression. The combined high expression group (both 
Ang-2 and VEGFA above median) was compared against 
tumors with either one or both Ang-2 and VEGFA 
expressed below median. The significance of Ang-2 and/or 
VEGFA expression for survival was assessed by log-rank 
testing (univariate) and Cox regressions (multivariate), 
and compared with the known prognostic factors age at 
diagnosis (≤ or >55 years) and Karnofsky performance 
scores (KPS, ≤ or >60). All variables with a significance 
level ≤0.05 were included in the multivariate analysis. 
Immunohistochemistry
GBM tissue sections were stained with antibodies 
against α-SMA (1A4, Dako, Glostrup, Denmark) and ColIV 
(MP Biomedicals, Santa Ana, CA, USA). The staining for 
α-SMA and ColIV were analyzed as described previously 
for the assessment of vascular parameters  [48]. For the 
quantification of proliferating endothelial cells tissue 
sections from proneural (PN) and mesenchymal (MES) 
GBMs were double-stained for CD34 (QBEnd10, Beckman 
Coulter, Marseille, France) and Ki-67 (MIB1, Dako). 
qRT-PCR
RNA was purified from snap-frozen GBM samples 
or in vitro tissue cultures and reverse-transcribed to 
cDNA. Samples were analyzed either using previously 
described custom-designed Taqman Micro Fluidic Cards 
(Applied Biosystems, Foster City, CA, USA) [48] or 
individual gene expression (Taqman) assays for IL8, 
STAT3, CEBPB, TAZ, RPS27 or GAPDH on a Viia™ 7 
real-time PCR system (Applied Biosystems).
Cell culture and recombinant proteins
U87 cells were maintained in DMEM/F-12 
(Lonza, Verviers, Belgium) supplemented with 1% fetal 
bovine serum (FBS, Sigma-Aldrich, Munich, Germany) 
and 1% penicillin/streptomycin solution (pen/strep, 
Lonza). Human dermal microvascular endothelial cells 
(HMEC-1) were kindly provided by Dr. E.W. Ades 
(CDC, Atlanta, GA, USA) [49] via Prof. G. Molema 
and the UMCG Endothelial Cell Facility and maintained 




Number of patients (n) 525 151 28
Mean age at diagnosis (95% CI) 58 (56–59) - 54 (48–59)
Median OS in days (range) 327 (2–3881) 509 (8–3614) 353 (62–1447)
Male sex (%) 320 (61) 79 (62%)* 18 (64)
Female sex (%) 205 (39) 48 (38%)* 10 (36)
*The gender of 24 patients was not available from the database.
Table 2: Univariate and multivariate analyses of possible prognostic parameters for OS of GBM patients in the TCGA 
and REMBRANDT cohort
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
TCGA cohort (n = 525)
ANGPT2 1.344 (1.103–1.637) 0.003 1.015 (0.745–1.384) 0.924
VEGFA 1.260 (1.036–1.532) 0.021 0.952 (0.712–1.273) 0.740
ANGPT2*VEGFA 1.524 (1.238–1.875) <0.001 1.562 (1.021–2.388) 0.040
REMBRANDT cohort (n = 151)
ANGPT2 1.212 (0.869–1.690) 0.256
VEGFA 1.261 (0.905–1.758) 0.171
ANGPT2*VEGFA 1.518 (1.055–2.185) 0.024
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in M-199 medium (Lonza) supplemented with 10% 
FBS, 10% human serum (Sigma-Aldrich), pen/strep 
and L-glutamine (Lonza). GSCs were maintained in 
DMEM/F12 (Lonza) supplemented with 10% B27 (Life 
Technologies, Bleiswijk, the Netherlands), 20 ng/ml bFGF 
and EGF (Life Technologies) and pen/strep. Carrier-free 
recombinant human VEGFA165 (from here on referred to 
as VEGFA), Ang-2 and IL-8 were obtained commercially 
(R&D Systems, Minneapolis, MN, USA).
Proliferation assay
For the evaluation of effects on proliferation the 
Chemicon® 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrasodium bromide (MTT) cell proliferation assay was 
performed according to the manufacturer’s instructions 
(Merck Millipore, Darmstadt, Gemany). Each condition 
was assessed in triplicate and averaged data from three 
independent assays are plotted relative to the control.
Apoptosis assay
Effects on apoptosis were assessed through staining 
for Cleaved Caspase 3 (Clone Asp175, Cell Signaling 
Technology, Danvers, MA, USA). A total of 5 images 
was quantified per condition and averaged data from three 
independent experiments are plotted relative to the control.
Protein secretion
IL-8 protein secretion levels were measured using 
a human IL-8 enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s protocol (R&D 
Systems).
Capillary-like tube formation assay
After 24 hour serum starvation 5 × 103 HMEC-1 cells 
were seeded on growth factor-reduced Matrigel® in µ-Slides 
for Angiogenesis (Ibidi, Munich, Germany). Recombinant 
proteins (Ang-2 and/or VEGFA) were added to serum-free 
HMEC-1 medium at indicated amounts, or  in the case 
of CM experiments the GSC CM was added to HMEC-1 
cells cultured in serum-free medium with a minimal CM 
concentration of 75%. After 5 hours incubation at 37° C 
each well was photographed and image analysis was carried 
out using Angiogenesis Analyzer [50] in ImageJ.
Statistical analysis
All statistical analyses were performed using SPSS 
software version 22.0 (SPSS, Chicago, IL, USA), and 
visualized using Graphpad Prism version 5 (Graphpad 
Software Inc, San Diego, CA, USA). Differences between 
groups were determined by a one-way ANOVA or t-test 
when data were normally distributed, and by a Kruskal–
Wallis test or Mann–Whitney U test when data were not 
normally distributed. The multiple group comparisons 
were followed up by either Tukey’s or Dunn’s post-hoc 
tests. Reported correlations concern Pearson r correlations. 
P-values < 0.05 were considered significant and in all 
cases exact two-sided P-values were reported.
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